Effects of vedolizumab on health-related quality of life in patients with ulcerative colitis: results from the randomised GEMINI 1 trial-Reference-Cited by-同舟云学术

登录注册会员服务联系我们

Effects of vedolizumab on health-related quality of life in patients with ulcerative colitis: results from the randomised GEMINI 1 trial

Published:2016-11-17 Issue:2 Volume:45 Page:264-275
ISSN:0269-2813
Container-title:Alimentary Pharmacology & Therapeutics
language:en
Short-container-title:Aliment Pharmacol Ther

Author:

Feagan B. G.¹,Patel H.²,Colombel J.-F.³,Rubin D. T.⁴,James A.⁵,Mody R.⁶,Lasch K.⁷

Affiliation:

1. Robarts Clinical Trials; Robarts Research Institute; University of Western Ontario; London ON Canada

2. Immensity Consulting, Inc.; Chicago IL USA

3. Icahn School of Medicine at Mount Sinai; New York NY USA

4. University of Chicago Medicine Inflammatory Bowel Disease Center; Chicago IL USA

5. Takeda Development Centre Europe Ltd.; London UK

6. Takeda Development Center Americas, Inc.; Deerfield IL USA

7. Takeda Pharmaceuticals USA, Inc.; Deerfield IL USA

Funder

Millennium Pharmaceuticals, Inc.

Publisher

Wiley

Subject

Pharmacology (medical),Gastroenterology,Hepatology

Link

http://onlinelibrary.wiley.com/wol1/doi/10.1111/apt.13852/fullpdf

Reference41 articles.

1. Relationship between disease severity and quality of life and assessment of health care utilization and cost for ulcerative colitis in Australia: a cross-sectional, observational study;Gibson;J Crohns Colitis,2014

2. Quality of life of patients with ulcerative colitis: past, present, and future;Irvine;Inflamm Bowel Dis,2008

3. Impact of inflammatory bowel disease on quality of life: results of the European Federation of Crohn's and Ulcerative Colitis Associations (EFCCA) patient survey;Ghosh;J Crohns Colitis,2007

4. Health-related quality of life in patients with inflammatory bowel disease: a single-center experience;Kalafateli;Ann Gastroenterol,2013

5. Clinical factors that impair health-related quality of life in ulcerative colitis patients vary with the disease duration;Kuriyama;Eur J Gastroenterol Hepatol,2008

Cited by 41 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Systematic Literature Review: Ability of the IBDQ-32 to Detect Meaningful Change in Ulcerative Colitis Health Indicators;Inflammatory Bowel Diseases;2023-12-27

2. Mirikizumab Improves Quality of Life in Patients With Moderately-to-Severely Active Ulcerative Colitis: Results From the Phase 3 LUCENT-1 Induction and LUCENT-2 Maintenance Studies;Crohn's & Colitis 360;2023-10-01

3. Quality of Life (QoL) in Patients with Chronic Inflammatory Bowel Diseases: How Much Better with Biological Drugs?;Journal of Personalized Medicine;2023-06-02

4. Safety and Effectiveness of Vedolizumab in Patients with Moderate-to-Severe Ulcerative Colitis: An Interim Analysis of a Japanese Post-Marketing Surveillance Study;Advances in Therapy;2023-05-04

5. Induction and Maintenance Treatment With Upadacitinib Improves Health-Related Quality of Life in Patients With Moderately to Severely Active Ulcerative Colitis: Phase 3 Study Results;Inflammatory Bowel Diseases;2023-01-16

同舟云学术

1.学者识别学者识别

2.学术分析学术分析

3.人才评估人才评估

"同舟云学术"是以全球学者为主线，采集、加工和组织学术论文而形成的新型学术文献查询和分析系统，可以对全球学者进行文献检索和人才价值评估。用户可以通过关注某些学科领域的顶尖人物而持续追踪该领域的学科进展和研究前沿。经过近期的数据扩容，当前同舟云学术共收录了国内外主流学术期刊6万余种，收集的期刊论文及会议论文总量共计约1.5亿篇，并以每天添加12000余篇中外论文的速度递增。我们也可以为用户提供个性化、定制化的学者数据。欢迎来电咨询！咨询电话：010-8811{复制后删除}0370

www.globalauthorid.com

TOP

Copyright © 2019-2024 北京同舟云网络信息技术有限公司
京公网安备11010802033243号京ICP备18003416号-3